Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966) issued an announcement. On October 23, 2026, Corning Jerry Biopharmaceuticals (Hong Kong) Co., Ltd. (the subscriber), a wholly-owned subsidiary of the Company, delivered an exercise notice under the warrants to Pathos AI along with its fourth revised and re-arranged investor rights agreement, the fourth revised and rearranged priority purchase rights and co-sale agreement and the fourth revised and re-arranged voting agreement, and completed payment of the exercise price.
The subscribers have chosen to subscribe and Pathos AI has issued 4.7204 million Series E preferred shares of Pathos AI, with an exercise price of US$13.24050 per share, which is equivalent to a total subscription price of approximately US$62.5 million.
The exercise has enabled the Group to participate as a shareholder in Pathos AI's potential value creation, and Pathos AI has been granted an exclusive license to develop and commercialize JSKN016 within the licensed region. The Board believes that the exercise will further align the Group's interests with Pathos AI in the global development and commercialization of JSKN016. At the same time, the Group will retain its exclusive rights in mainland China, Hong Kong, Macau and Taiwan, and will enable the Group to benefit from Pathos AI's capabilities in precision medicine, artificial intelligence-driven drug development and oncology clinical development. Subscription shares are purchased at the same price per share paid by other Series E investors.